Biohaven pharmaceuticals and weill cornell medicine collaborate to initiate proof of concept trial with cgrp receptor antagonist in plaque psoriasis

New haven, conn., nov. 16, 2020 /prnewswire/ -- biohaven pharmaceutical holding company ltd. (nyse: bhvn), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that dr. richard granstein, m.d., chairman of dermatology...

BHVN Ratings Summary

BHVN Quant Ranking